abstract |
Use of direct or indirect selective inhibitors of factor Xa which act via antithrombin III, in combination with one or more compounds with anti-platelet aggregation activity, for the preparation of medicines intended to prevent and to treat thromboembolic arterial diseases, substantially as described in the specification. 2656 י" ב בתשרי התשס" ה - September 27, 2004 |